Patient, disease, and treatment characteristics
| Characteristic . | All∗ N = 23 . | HMB n = 12∗ . | LMB n = 11∗ . |
|---|---|---|---|
| Age, y | |||
| Median (IQR) | 45 (36-58) | 41 (32-49) | 56 (40-59) |
| Range | 27-72 | 27-60 | 30-72 |
| Sex | |||
| Male | 13 (57) | 6 (50) | 7 (64) |
| Female | 10 (43) | 6 (50) | 4 (36) |
| Race | |||
| White | 18 (82) | 10 (91) | 8 (73) |
| Asian | 4 (18) | 1 (9) | 3 (27) |
| Unknown | 1 | 1 | 0 |
| Ethnicity | |||
| Hispanic or Latino | 2 (9) | 2 (18) | 0 (0) |
| Not Hispanic or Latino | 20 (91) | 9 (92) | 11 (100) |
| Unknown | 1 | 1 | 0 |
| B-ALL subtype | |||
| BCR::ABL1 fusion | 5 (22) | 3 (25) | 2 (18) |
| KMT2A rearrangement | 3 (13) | 1 (8.3) | 2 (18) |
| Other | 15 (65) | 8 (67) | 7 (64) |
| Pre-LD marrow blasts (%) | |||
| Median (IQR) | 7.70 (0.01-52.85) | 52.85 (23.50-80.35) | 0.01 (0.00-0.01) |
| Range | 0.00-97.00 | 7.70-97.00 | 0.00-1.50 |
| Pre-LD EMD | 14 (61) | 4 (33) | 10 (91) |
| Pre-LD bulky EMD (≥ 5 cm) | 7 (30) | 1 (8.3) | 6 (55) |
| Pre-LD CNS disease† | |||
| CNS-1 | 15 (68) | 6 (50) | 9 (90) |
| CNS-2a | 2 (9.1) | 1 (8.3) | 1 (10) |
| CNS-2b | 4 (18) | 4 (33) | 0 (0) |
| CNS-3a | 1 (4.5) | 1 (8.3) | 0 (0) |
| Unknown | 1 | 0 | 1 |
| Prior allo-HCT | 15 (65) | 7 (58) | 8 (73) |
| Prior blinatumomab | 13 (57) | 6 (50) | 7 (64) |
| Prior inotuzumab ozogamicin | 12 (52) | 7 (58) | 5 (45) |
| Number of previous therapies (excluding HCT) | |||
| Median (IQR) | 3 (3-4) | 4 (3-5) | 3 (2-4) |
| Range | 1-6 | 2-6 | 1-5 |
| Bridging therapy after leukapheresis | 15 (65) | 10 (83) | 5 (45) |
| JCAR021 dose | |||
| 7 × 104/kg (starting dose for the HMB cohort) | 3 (13) | 3 (25) | 0 (0) |
| 2 × 105/kg | 4 (17) | 4 (33) | 0 (0) |
| 7 × 105/kg (starting dose for the LMB cohort) | 8 (35) | 5 (42) | 3 (27) |
| 2 × 106/kg | 7 (30) | 0 (0) | 7 (64) |
| 7 × 106/kg | 1 (4.3) | 0 (0) | 1 (9.1) |
| Characteristic . | All∗ N = 23 . | HMB n = 12∗ . | LMB n = 11∗ . |
|---|---|---|---|
| Age, y | |||
| Median (IQR) | 45 (36-58) | 41 (32-49) | 56 (40-59) |
| Range | 27-72 | 27-60 | 30-72 |
| Sex | |||
| Male | 13 (57) | 6 (50) | 7 (64) |
| Female | 10 (43) | 6 (50) | 4 (36) |
| Race | |||
| White | 18 (82) | 10 (91) | 8 (73) |
| Asian | 4 (18) | 1 (9) | 3 (27) |
| Unknown | 1 | 1 | 0 |
| Ethnicity | |||
| Hispanic or Latino | 2 (9) | 2 (18) | 0 (0) |
| Not Hispanic or Latino | 20 (91) | 9 (92) | 11 (100) |
| Unknown | 1 | 1 | 0 |
| B-ALL subtype | |||
| BCR::ABL1 fusion | 5 (22) | 3 (25) | 2 (18) |
| KMT2A rearrangement | 3 (13) | 1 (8.3) | 2 (18) |
| Other | 15 (65) | 8 (67) | 7 (64) |
| Pre-LD marrow blasts (%) | |||
| Median (IQR) | 7.70 (0.01-52.85) | 52.85 (23.50-80.35) | 0.01 (0.00-0.01) |
| Range | 0.00-97.00 | 7.70-97.00 | 0.00-1.50 |
| Pre-LD EMD | 14 (61) | 4 (33) | 10 (91) |
| Pre-LD bulky EMD (≥ 5 cm) | 7 (30) | 1 (8.3) | 6 (55) |
| Pre-LD CNS disease† | |||
| CNS-1 | 15 (68) | 6 (50) | 9 (90) |
| CNS-2a | 2 (9.1) | 1 (8.3) | 1 (10) |
| CNS-2b | 4 (18) | 4 (33) | 0 (0) |
| CNS-3a | 1 (4.5) | 1 (8.3) | 0 (0) |
| Unknown | 1 | 0 | 1 |
| Prior allo-HCT | 15 (65) | 7 (58) | 8 (73) |
| Prior blinatumomab | 13 (57) | 6 (50) | 7 (64) |
| Prior inotuzumab ozogamicin | 12 (52) | 7 (58) | 5 (45) |
| Number of previous therapies (excluding HCT) | |||
| Median (IQR) | 3 (3-4) | 4 (3-5) | 3 (2-4) |
| Range | 1-6 | 2-6 | 1-5 |
| Bridging therapy after leukapheresis | 15 (65) | 10 (83) | 5 (45) |
| JCAR021 dose | |||
| 7 × 104/kg (starting dose for the HMB cohort) | 3 (13) | 3 (25) | 0 (0) |
| 2 × 105/kg | 4 (17) | 4 (33) | 0 (0) |
| 7 × 105/kg (starting dose for the LMB cohort) | 8 (35) | 5 (42) | 3 (27) |
| 2 × 106/kg | 7 (30) | 0 (0) | 7 (64) |
| 7 × 106/kg | 1 (4.3) | 0 (0) | 1 (9.1) |